CN111135198A - Composition for inhibiting obesity - Google Patents
Composition for inhibiting obesity Download PDFInfo
- Publication number
- CN111135198A CN111135198A CN202010125402.XA CN202010125402A CN111135198A CN 111135198 A CN111135198 A CN 111135198A CN 202010125402 A CN202010125402 A CN 202010125402A CN 111135198 A CN111135198 A CN 111135198A
- Authority
- CN
- China
- Prior art keywords
- spirulina
- poloxamer
- obesity
- composition
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a composition for inhibiting obesity, which comprises poloxamer and spirulina. The composition for inhibiting obesity and the oral solid preparation thereof are an organic whole, and the components generate complementary advantages through mutual synergistic effect, so that the safe and efficient obesity inhibition effect is realized.
Description
Technical Field
The present invention relates to a composition, and more particularly, to an obesity-inhibiting composition.
Background
Obesity is a chronic metabolic disease in which fat is excessively accumulated in the body to threaten health. Obesity is mainly related to diet, work and rest, constitution, heredity, age, sex, nature of work, mental and geographical features. With the improvement of the living standard of residents, unreasonable dietary structure, less grain intake, more high-fat and high-calorie food intake, lack of physical exercise and other factors, overweight and obesity phenomena are increased, the incidence rate of the diseases in cities of China is about 15-20%, and the diseases tend to increase and become younger year by year.
With the rapid increase of the incidence of obesity, obesity-related diseases are also in a growing trend. Obesity is an important inducing factor of stroke in addition to hypertension and diabetes. The waist of a male is more than 85 cm, the waist of a female is more than 80 cm, fat is mainly accumulated in the abdominal wall and the abdominal cavity, and the male is central obesity and is more likely to induce chronic diseases such as diabetes, cardiovascular diseases and the like. Meanwhile, obesity is also related to the occurrence of tumors such as breast cancer, cervical cancer, prostate cancer, colorectal cancer and the like. Besides adult obesity, the problem of obesity in children and teenagers is not negligible. Obesity not only can have great influence on the cardio-pulmonary function development, blood circulation, metabolism and physical indicators of children and teenagers, leaves hidden dangers for the occurrence of chronic diseases in the adult period such as hypertension, diabetes, metabolic syndrome and the like, but also has long-term adverse influence on the development of personality, character, temperament, emotion and socialization capability of the children and the teenagers.
Current methods of treating obesity include diet control, exercise therapy, drug therapy, surgical therapy and traditional chinese medicine therapy. Diet control and exercise therapy are often difficult for obese patients to adhere to and rebound easily. Drugs for obesity are broadly divided into two main groups: namely chemical drugs (western medicines), traditional Chinese medicines and compound medicines, and the western medicines have the problems of drug side effects and drug resistance. The surgical treatment of gastric short-circuit surgery, gastroplasty and the like has potential risks of complication of malabsorption, anemia and narrow pipelines, and the most important problem is that the reason for the occurrence of obesity cannot be solved fundamentally, so that the problem of obesity rebound cannot be solved.
In a word, the existing treatment methods aiming at obesity have the problems or defects of side effects, drug resistance and the like, an oral solid preparation which can be stored for a long time, is convenient to apply and safe and does not have side effects and effectively inhibits obesity is lacked, and the development of the preparation for inhibiting obesity has great significance for solving the problem of obesity and improving the life quality of obese people.
Disclosure of Invention
An object of the present invention is to solve at least the above problems and/or disadvantages and to provide at least the advantages described hereinafter.
In order to overcome the bottleneck of the lack of the oral solid preparation which can effectively inhibit obesity, can be stored for a long time, is convenient to use, is safe and has no side effect, the invention also aims to provide the composition for inhibiting obesity and the oral solid preparation thereof.
Therefore, the technical scheme provided by the invention is as follows:
a composition for inhibiting obesity comprises poloxamer and spirulina.
Preferably, in the composition for inhibiting obesity, the weight ratio of the poloxamer to the spirulina is 20: 1-5: 1
More preferably, in the composition for inhibiting obesity, the mass ratio of the poloxamer to the spirulina is 15: 1-10: 1.
Most preferably, in the composition for inhibiting obesity, the weight ratio of the poloxamer to the spirulina is 12: 1.
Preferably, in the composition for inhibiting obesity, the composition is an oral solid preparation, and the oral solid preparation comprises tablets, granules, capsules, dripping pills and pellets.
Preferably, the composition for inhibiting obesity further comprises peanut coat extract, salix populi extract and radix angelicae extract.
Preferably, the composition for inhibiting obesity comprises, by weight, 5-20 parts of poloxamer, 1 part of spirulina, 4-10 parts of peanut coat extract, 3-5 parts of salix integra extract and 2-4 parts of radix angelicae extract.
Preferably, the composition for inhibiting obesity comprises 12 parts of poloxamer, 1 part of spirulina, 7 parts of peanut coat extract, 4 parts of salix populi extract and 5 parts of radix angelicae extract in parts by weight.
Preferably, in the composition for inhibiting obesity, the preparation method of the tablet of the composition comprises the following steps: poloxamer, spirulina, xylitol, citric acid, crosslinked polyvinylpyrrolidone, micropowder silica gel and magnesium stearate according to the mass ratio of 84: 7: 1: 2: 8: 0.5: 0.5, weighing, mixing and tabletting to obtain tablets;
the preparation method of the granules of the composition comprises the following steps: poloxamer, spirulina, xylitol, citric acid, cross-linked polyvinylpyrrolidone and polyvinyl alcohol 6000 in a mass ratio of 84: 7: 1: 2: 4: 15, weighing, mixing, spraying absolute ethyl alcohol for wetting, extruding to prepare wet granules, and drying to obtain granules;
the preparation method of the capsule of the composition comprises the following steps: the poloxamer, the spirulina, the xylitol, the citric acid and the cross-linked polyvinylpyrrolidone are mixed according to the mass ratio of 84: 7: 1: 2: 8, weighing, uniformly mixing, and filling into hard capsules to obtain capsules;
the preparation method of the pellet preparation of the composition comprises the following steps: the poloxamer, the spirulina, the xylitol and the citric acid are mixed according to the mass ratio of 84: 7: 10: 2, weighing xylitol, preparing into a pellet core, placing into a coating pan, uniformly mixing poloxamer, spirulina and citric acid, adding into the coating pan one by one, spraying absolute ethyl alcohol for wetting, and preparing into a pellet by a coating pan method;
the preparation method of the dripping pill preparation of the composition comprises the following steps: the poloxamer, the spirulina, the xylitol and the citric acid are mixed according to the mass ratio of 84: 7: 10: 2, weighing, heating in water bath to melt poloxamer, keeping the temperature at 70 ℃, adding xylitol and citric acid, melting, mixing, adding spirulina, stirring to obtain molten medicinal liquid, dripping into 0 deg.C simethicone, and condensing to obtain dripping pill.
Preferably, in the composition for inhibiting obesity, a flavoring agent, a stabilizer, a filler, a disintegrant, a lubricant, a glidant, a bacteriostatic agent and a pH regulator are added into the oral solid preparation.
The invention at least comprises the following beneficial effects:
the composition for inhibiting obesity and the oral solid preparation thereof overcome the bottleneck that the oral solid preparation which can be stored for a long time, is convenient to apply and has no side effect and effectively inhibits obesity is not available at present, and have the following advantages: (1) the stability is good, the long-term storage is suitable, and the taking is simple and convenient; (2) the safety is high, and the problems of side effects and drug resistance of the drug are solved; (3) without the potential risks of malabsorption, anemia and stenosis of the canal caused by operative treatment such as gastric short-circuit surgery, gastroplasty and the like. (4) Ensure the nutrition supply of essential protein, amino acid and the like of the organism. (5) The immunity of the organism is not affected.
The composition for inhibiting obesity and the oral solid preparation thereof are an organic whole, and the components generate complementary advantages through mutual synergistic effect, so that the safe and efficient obesity inhibition effect is realized.
Additional advantages, objects, and features of the invention will be set forth in part in the description which follows and in part will become apparent to those having ordinary skill in the art upon examination of the following or may be learned from practice of the invention.
Detailed Description
The present invention is described in further detail below to enable those skilled in the art to practice the invention with reference to the description.
It will be understood that terms such as "having," "including," and "comprising," as used herein, do not preclude the presence or addition of one or more other elements or groups thereof.
The present invention provides a composition for suppressing obesity, comprising: including poloxamers and spirulina.
Poloxamers (poloxamers) are polyoxyethylene polyoxypropylene ether block copolymers, available under the trade name Pluronic, and are a novel class of polymeric nonionic surfactants. Poloxamer has no physiological activity, no hemolytic activity, no irritation to skin, and low toxicity, and can be used as adhesive, coating material, etc. to prepare tablet, capsule, pellet, etc. for sustained release and controlled release. The spirulina is a low class prokaryotic organism, has various health care effects, is an accelerant of a broad spectrum immune system, is a high protein food, is rich in vegetable protein and 17 amino acids, and has the effects of preventing and resisting cancers, eliminating free radicals of a human body, enhancing the immune function of the human body and delaying senescence. However, spirulina itself has unpleasant fishy smell, has poor taste and strong stickiness, and is not suitable for direct oral administration.
Through a large number of experimental researches, the applicant innovatively combines poloxamer and spirulina to prepare a stable solid oral preparation for inhibiting obesity. The applicant finds that poloxamer has phase transition characteristics, and orally administers to experimental animals to find that poloxamer forms nonabsorbent high-hydrophilicity viscous solution in gastrointestinal tracts, slows down gastric emptying and intestinal peristalsis, enables the experimental animals to have a feeling of 'pseudo-satiety', and accordingly suppresses appetite and effectively inhibits obesity. In addition, the research of the applicant finds that the spirulina has the effects of improving the immunity and the like, and can play a complementary role in advantages by being matched with the application of poloxamer: poloxamer covers the fishy smell of spirulina and improves the viscosity of spirulina in gastrointestinal tract; the spirulina is rich in vegetable protein and 17 amino acids, and can maintain the nutrition supply of protein and amino acids necessary for the body while suppressing appetite by cooperating with poloxamer.
In the scheme, the weight ratio of the poloxamer to the spirulina is preferably 20: 1-5: 1. More preferably, the weight ratio of the poloxamer to the spirulina is 15: 1-10: 1. Most preferably, the poloxamer and the spirulina are in a mass ratio of 12: 1.
In some embodiments of the present invention, preferably, the composition is an oral solid preparation, and the oral solid preparation includes tablets, granules, capsules, dripping pills and pellets.
In some of the embodiments of the present invention, preferably, the process for preparing tablets of the composition comprises the steps of: poloxamer, spirulina, xylitol, citric acid, crosslinked polyvinylpyrrolidone, micropowder silica gel and magnesium stearate according to the mass ratio of 84: 7: 1: 2: 8: 0.5: 0.5, weighing, mixing and tabletting to obtain tablets;
the preparation method of the granules of the composition comprises the following steps: poloxamer, spirulina, xylitol, citric acid, cross-linked polyvinylpyrrolidone and polyvinyl alcohol 6000 in a mass ratio of 84: 7: 1: 2: 4: 15, weighing, mixing, spraying absolute ethyl alcohol for wetting, extruding to prepare wet granules, and drying to obtain granules;
the preparation method of the capsule of the composition comprises the following steps: the poloxamer, the spirulina, the xylitol, the citric acid and the cross-linked polyvinylpyrrolidone are mixed according to the mass ratio of 84: 7: 1: 2: 8, weighing, uniformly mixing, and filling into hard capsules to obtain capsules;
the preparation method of the pellet preparation of the composition comprises the following steps: the poloxamer, the spirulina, the xylitol and the citric acid are mixed according to the mass ratio of 84: 7: 10: 2, weighing xylitol, preparing into a pellet core, placing into a coating pan, uniformly mixing poloxamer, spirulina and citric acid, adding into the coating pan one by one, spraying absolute ethyl alcohol for wetting, and preparing into a pellet by a coating pan method;
the preparation method of the dripping pill preparation of the composition comprises the following steps: the poloxamer, the spirulina, the xylitol and the citric acid are mixed according to the mass ratio of 84: 7: 10: 2, weighing, heating in water bath to melt poloxamer, keeping the temperature at 70 ℃, adding xylitol and citric acid, melting, mixing, adding spirulina, stirring to obtain molten medicinal liquid, dripping into 0 deg.C simethicone, and condensing to obtain dripping pill.
In some embodiments of the present invention, it is preferable that a flavoring agent, a stabilizer, a filler, a disintegrant, a lubricant, a glidant, a bacteriostatic agent and a pH adjusting agent are added to the oral solid preparation.
In some embodiments of the present invention, it is preferable that the peanut skin extract, the salix populi extract and the angelica dahurica extract are further included. In the scheme, the composition preferably comprises 5-20 parts of poloxamer, 1 part of spirulina, 4-10 parts of peanut coat extract, 3-5 parts of salix populi extract and 2-4 parts of radix angelicae extract in parts by weight. Most preferably, the composition comprises 12 parts of poloxamer, 1 part of spirulina, 7 parts of peanut coat extract, 4 parts of salix populi extract and 5 parts of radix angelicae extract in parts by weight. Due to the combined use of the angelica dahurica extract and the salix populi extract, the heat clearing effect is achieved, the poloxamer and the spirulina slow down the emptying of the stomach and the peristalsis of the intestine, the satiety is generated, and meanwhile, the spirulina, peanut coat extract and the like provide rich nutrition, so that the weight is reasonably and effectively reduced. In addition, the applicant has unexpectedly found that the composition can heal diabetic ulcer wounds after the peanut coat extract, the salix populi extract and the radix angelicae extract are added. The combination of the angelica dahurica extract and the salix populi extract has the effects of clearing away heat and toxic materials, solidifying poloxamer and the like, so that when the granules of the composition are applied to a Wistar rat with a diabetic ulcer model, the healing process of the ulcer wound of the rat is quicker, and the side effects of scar bleeding and the like are less.
In order to make the technical solution of the present invention better understood by those skilled in the art, the following examples are now provided for illustration:
example 1 preparation of oral solid preparation of composition for suppressing obesity
Experimental groups: the oral solid preparation was prepared by weighing the components according to the compositions of the experimental groups of table 1 and following the following procedure.
(1) Preparation of tablets of the obesity-inhibiting composition: poloxamer, spirulina, xylitol, citric acid, crosslinked polyvinylpyrrolidone, micropowder silica gel and magnesium stearate according to the mass ratio of 84: 7: 1: 2: 8: 0.5: 0.5, mixing, and tabletting to obtain tablet of the composition for inhibiting obesity.
(2) Preparation of granules of the composition for inhibiting obesity: poloxamer, spirulina, xylitol, citric acid, cross-linked polyvinylpyrrolidone and polyvinyl alcohol 6000 in a mass ratio of 84: 7: 1: 2: 4: 15, weighing, mixing, spraying absolute ethyl alcohol for wetting, extruding and pressing into wet granules by a 15-mesh sieve, volatilizing the ethyl alcohol, shaping by the 15-mesh sieve, and uniformly mixing to obtain the granules of the composition for inhibiting obesity.
(3) Preparation of capsules of the composition for inhibiting obesity: the poloxamer, the spirulina, the xylitol, the citric acid and the cross-linked polyvinylpyrrolidone are mixed according to the mass ratio of 84: 7: 1: 2: 8, weighing, uniformly mixing, and filling into hard capsules to obtain the capsule of the composition for inhibiting the obesity.
(4) Preparation of pellets of the obesity-inhibiting composition: the poloxamer, the spirulina, the xylitol and the citric acid are mixed according to the mass ratio of 84: 7: 10: 2, weighing xylitol, preparing into pill cores, placing into a coating pan, uniformly mixing poloxamer, spirulina and citric acid, adding into the coating pan one by one, spraying absolute ethyl alcohol for wetting, and preparing the pellet by a coating pan method to obtain the pellet of the composition for inhibiting obesity.
(5) Preparing a dripping pill of the composition for inhibiting obesity: the poloxamer, the spirulina, the xylitol and the citric acid are mixed according to the mass ratio of 84: 7: 10: 2 weighing, heating in water bath to melt poloxamer, keeping the temperature at 70 deg.C, adding xylitol and citric acid, melting, mixing, adding Spirulina, stirring to obtain molten medicinal liquid, dripping into 0 deg.C simethicone, and condensing to obtain dripping pill.
Control group: oral solid preparations of the control group were prepared according to the composition of the control group of table 1 with reference to that of the experimental group.
TABLE 1 Experimental group and control group of oral solid preparation of obesity-inhibiting composition
Note: "√" represents that the item component is a column-named component; "" indicates that the component is replaced by a new component; the rectally administered dropping pills of control group 9 were rectally administered from an animal anus plug.
Example 2 evaluation of Effect of Using the formulation of obesity-suppressing composition
(1) Obese model animal
According to the literature, a fat model of the miniature pig is established, and the method is briefly described as follows: and (3) feeding the Bama miniature pigs with high-fat and high-sugar feed for 30 weeks, comparing the fed Bama miniature pigs with the Bama miniature pigs fed with normal diet, measuring the body form factor, scanning the fat content by CT, collecting blood, detecting biochemical indexes, and determining the success of the obesity model.
(2) Stability investigation and application Effect evaluation
And (3) stability investigation: the oral solid preparations of the experimental group and the control group were subjected to accelerated tests, and left for 6 months at a temperature of 40. + -.2 ℃ and a relative humidity of 75. + -.5%, and the physicochemical properties and stability thereof were observed and evaluated, and the results are shown in Table 2.
Evaluation of application effects: the obesity model pigs are randomly divided into 24 groups, 5 pigs in each group are respectively given to preparations of an experimental group and a control group according to a preparation administration method, the body form factor and the change of the fat content of CT scanning are measured once a day after 3 weeks, blood is collected to detect the biochemical indexes such as total cholesterol, high-density lipoprotein cholesterol, triglyceride and the like, and the obesity inhibition effect of the model pigs is comprehensively evaluated according to the biochemical indexes. The obesity inhibition effect of the model pig is quantitatively evaluated according to the comprehensive obesity inhibition effect, the score is divided into 100 grades from 1 to 100, and the higher the value is, the better the obesity inhibition effect is. The results of evaluation of the obesity-suppressing effect of each group are shown in Table 2.
TABLE 2 obesity inhibitory Effect of oral solid preparations of Experimental group and control group
As can be seen from the stability examination results in Table 2, the oral solid preparations of the experimental group and the control group have no any physicochemical change after the accelerated test, the preparation has good standing stability, and the storage life can reach 2 years.
As can be seen from the scores of the obesity inhibition effect in the table 2, the oral solid preparation in each experimental group has a good obesity inhibition effect on the model pig, and the scores of the effects of the experimental groups 10-15 are all over 90. In contrast, the control formulation scored significantly worse obesity inhibition in the model pigs than the experimental group, especially control 9, without any effect, demonstrating the importance of the oral route of administration. The groups of the control groups 1-4 are different from the experimental group, the scores are poor, and the irreplaceability of the experimental group is proved. The scores of the control groups 5-8 are also poor, and the fact that the component mass ratio of the experimental group is innovative and cannot be changed randomly is proved. The results of animal experiments of obesity models show that the components in the oral solid preparation of the composition have good synergistic effect on inhibiting the obesity process.
The number of modules and the processing scale described herein are intended to simplify the description of the invention. The use, modifications and variations of the obesity inhibiting compositions of the present invention will be apparent to those skilled in the art.
While embodiments of the invention have been disclosed above, it is not limited to the applications listed in the description and the embodiments, which are fully applicable in all kinds of fields of application of the invention, and further modifications may readily be effected by those skilled in the art, so that the invention is not limited to the specific details without departing from the general concept defined by the claims and the scope of equivalents.
Claims (10)
1. A composition for inhibiting obesity, comprising a poloxamer and a spirulina.
2. The composition for inhibiting obesity according to claim 1, wherein the weight ratio of the poloxamer to the spirulina is 20: 1-5: 1.
3. The composition for inhibiting obesity according to claim 2, wherein the weight ratio of poloxamer to spirulina is 15: 1-10: 1.
4. The obesity inhibiting composition according to claim 3, wherein the poloxamer and the spirulina are in a mass ratio of 12: 1.
5. The obesity-inhibiting composition according to claim 1, wherein the composition is an oral solid preparation comprising tablets, granules, capsules, dripping pills and pellets.
6. The obesity inhibiting composition according to any one of claims 1 to 5, further comprising peanut coat extract, poplar willow extract and dahurian angelica root extract.
7. The composition for suppressing obesity according to claim 6, wherein the composition comprises 5-20 parts by weight of poloxamer, 1 part by weight of spirulina, 4-10 parts by weight of peanut coat extract, 3-5 parts by weight of salix populi extract and 2-4 parts by weight of radix angelicae extract.
8. The composition for suppressing obesity according to claim 6, wherein the composition comprises 12 parts of poloxamer, 1 part of spirulina, 7 parts of peanut coat extract, 4 parts of salix integra extract and 5 parts of angelica dahurica extract by weight.
9. The obesity inhibiting composition according to claim 5, wherein the tablet of the composition is prepared by a process comprising the steps of: poloxamer, spirulina, xylitol, citric acid, crosslinked polyvinylpyrrolidone, micropowder silica gel and magnesium stearate according to the mass ratio of 84: 7: 1: 2: 8: 0.5: 0.5, weighing, mixing and tabletting to obtain tablets;
the preparation method of the granules of the composition comprises the following steps: poloxamer, spirulina, xylitol, citric acid, cross-linked polyvinylpyrrolidone and polyvinyl alcohol 6000 in a mass ratio of 84: 7: 1: 2: 4: 15, weighing, mixing, spraying absolute ethyl alcohol for wetting, extruding to prepare wet granules, and drying to obtain granules;
the preparation method of the capsule of the composition comprises the following steps: the poloxamer, the spirulina, the xylitol, the citric acid and the cross-linked polyvinylpyrrolidone are mixed according to the mass ratio of 84: 7: 1: 2: 8, weighing, uniformly mixing, and filling into hard capsules to obtain capsules;
the preparation method of the pellet preparation of the composition comprises the following steps: the poloxamer, the spirulina, the xylitol and the citric acid are mixed according to the mass ratio of 84: 7: 10: 2, weighing xylitol, preparing into a pellet core, placing into a coating pan, uniformly mixing poloxamer, spirulina and citric acid, adding into the coating pan one by one, spraying absolute ethyl alcohol for wetting, and preparing into a pellet by a coating pan method;
the preparation method of the dripping pill preparation of the composition comprises the following steps: the poloxamer, the spirulina, the xylitol and the citric acid are mixed according to the mass ratio of 84: 7: 10: 2, weighing, heating in water bath to melt poloxamer, keeping the temperature at 70 ℃, adding xylitol and citric acid, melting, mixing, adding spirulina, stirring to obtain molten medicinal liquid, dripping into 0 deg.C simethicone, and condensing to obtain dripping pill.
10. The obesity inhibiting composition according to claim 5, wherein a flavoring agent, a stabilizer, a filler, a disintegrant, a lubricant, a glidant, a bacteriostatic agent and a pH regulator are added to the oral solid preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010125402.XA CN111135198B (en) | 2020-02-27 | 2020-02-27 | Composition for inhibiting obesity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010125402.XA CN111135198B (en) | 2020-02-27 | 2020-02-27 | Composition for inhibiting obesity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111135198A true CN111135198A (en) | 2020-05-12 |
| CN111135198B CN111135198B (en) | 2021-01-15 |
Family
ID=70528148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010125402.XA Active CN111135198B (en) | 2020-02-27 | 2020-02-27 | Composition for inhibiting obesity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111135198B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1105566A (en) * | 1994-11-25 | 1995-07-26 | 刘玉良 | Method for preparation of spirulina health-care products |
| CN1440762A (en) * | 2002-02-25 | 2003-09-10 | 杨孟君 | Slimming medicine and health food and the prepn process |
| CN1742753A (en) * | 2005-09-02 | 2006-03-08 | 夏鸿林 | Fat-reducing compound preparation |
| CN110464708A (en) * | 2019-07-12 | 2019-11-19 | 广州加原医药科技有限公司 | A kind of spirulina nanometer formulation and preparation method thereof |
-
2020
- 2020-02-27 CN CN202010125402.XA patent/CN111135198B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1105566A (en) * | 1994-11-25 | 1995-07-26 | 刘玉良 | Method for preparation of spirulina health-care products |
| CN1440762A (en) * | 2002-02-25 | 2003-09-10 | 杨孟君 | Slimming medicine and health food and the prepn process |
| CN1742753A (en) * | 2005-09-02 | 2006-03-08 | 夏鸿林 | Fat-reducing compound preparation |
| CN110464708A (en) * | 2019-07-12 | 2019-11-19 | 广州加原医药科技有限公司 | A kind of spirulina nanometer formulation and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 史建俊等: "泊洛沙姆在药剂应用中的研究进展", 《科技信息》 * |
| 陈冠敏等: "神藻减肥胶囊对肥胖大鼠减肥降脂效果的观察", 《海峡预防医学杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111135198B (en) | 2021-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008099397A2 (en) | Compositions and methods for enhancing transmucosal delivery | |
| AU2014305430B2 (en) | Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof | |
| JP2008521756A (en) | Novel formulation and preparation method of pyridoxal-5'-phosphate | |
| JP2006520803A (en) | Esterified fatty acid composition | |
| CN105343056A (en) | Oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application | |
| CN111135198B (en) | Composition for inhibiting obesity | |
| CN105380918A (en) | Acanthopanax trifoliatus polysaccharide tablet with blood sugar-reducing and health-care functions and preparation method thereof | |
| CN110201073B (en) | Traditional Chinese medicine composition for treating gouty arthritis and preparation method and application thereof | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN103356630B (en) | Containing pentoxifylline and the pharmaceutical composition of prucalopride and medical usage thereof | |
| CN106727480B (en) | Fex-3 is preparing the application in anti-obesity drug | |
| JP2013542975A (en) | Pharmaceutical compositions comprising citric acid and bicarbonate and their use for treating cystinuria | |
| JP2021529726A (en) | Chinese herbal composition for treating cancer pain and ascites, Chinese poultice and its preparation method | |
| JP6904589B2 (en) | Drugs with anti-stress, anxiolytic and antidepressant activity, and compositions based on them | |
| CN105380031A (en) | Health food and preparation method thereof | |
| KR101047796B1 (en) | Cold grass extract having an effect of improving insulin resistance and a product containing the same as an active ingredient | |
| CN115887396B (en) | Methanazol orally disintegrating tablet as well as preparation method and application thereof | |
| CN103550409B (en) | Pharmaceutical composition of a kind of fat-reducing and preparation method thereof | |
| CN115531365B (en) | Application of chlorogenic acid composition in preparation of medicines for preventing or treating pain | |
| CN102283832B (en) | Medicinal composition for preventing or treating hypertensive obese patient and application thereof | |
| CN112336830B (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
| TWI735658B (en) | Composition for reducing metabolic syndrome and application thereof | |
| CN1322860C (en) | Levo carnitine dropping pill and preparation thereof | |
| JP2020200301A (en) | Lipid combustion accelerator | |
| WO2020137687A1 (en) | Core body temperature improving agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |